PharmaCyte Biotech, Inc. (PMCB): Operating Cash Flow
-$5.15M
Year ended 2026-04-30
-$3.94M
Trailing 12 months to 2026-07-31
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | -$5.15M | n/m | 2026-07-29, From 2025-05-01 |
| 2025-04-30 | -$2.98M | n/m | 2026-07-29, From 2024-05-01 |
| 2024-04-30 | -$2.15M | n/m | 2025-08-11, From 2023-05-01 |
| 2023-04-30 | -$3.79M | n/m | 2024-08-13, From 2022-05-01 |
| 2022-04-30 | -$4.12M | n/m | 2023-07-31, From 2021-05-01 |
| 2021-04-30 | -$3.33M | n/m | 2022-07-28, From 2020-05-01 |
| 2020-04-30 | -$2.34M | n/m | 2021-08-10, From 2019-05-01 |
| 2019-04-30 | -$2.88M | n/m | 2020-08-13, From 2018-05-01 |
| 2018-04-30 | -$5.08M | n/m | 2019-08-13, From 2017-05-01 |
| 2017-04-30 | -$3.34M | n/m | 2018-07-20, From 2016-05-01 |
| 2016-04-30 | -$4.35M | n/m | 2017-07-27, From 2015-05-01 |
| 2015-04-30 | -$4.56M | n/m | 2016-07-29, From 2014-05-01 |
| 2014-04-30 | -$1.55M | n/m | 2016-07-29, From 2013-05-01 |
| 2013-04-30 | -$390.4K | n/m | 2013-07-29, From 2012-05-01 |
| 2012-04-30 | -$259.3K | n/m | 2013-07-29, From 2011-05-01 |
| 2011-04-30 | -$225.2K | n/a | 2012-08-14, From 2010-05-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | -$5.15M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $7.71M | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $9.96B | -13.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $117.42M | -33.1% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$4.47M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $292.07M | +1.6% |
| Biogen Inc. (BIIB) | 2025-12-31 | $2.20B | -23.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$18.92M | n/m |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $10.02B | -7.5% |
Compare PMCB, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗